Page 61 - Read Online
P. 61

Aguiar. Rare Dis Orphan Drugs J 2024;3:13  https://dx.doi.org/10.20517/rdodj.2023.56  Page 5 of 29

































                Figure  1.  Plasma  lyso-Gb3:  sub-analysis  by  gender  in  male  and  female  patients  with  Fabry  disease [46] . Lyso-Gb3:
                Globotriaosylsphingosine.


               However, the discriminative power of plasma lyso-Gb3 in male and female patients with variants of
               unknown significance, like p. R118C, p.R112H, and p.P60L, seems limited, as lyso-Gb3 is not increased in
               this  group  of  patients  (even  in  patients  with  histological  demonstration  of  Gb3  storage  in
               podocytes) [31,41,45,55,56] . Nonetheless, recently, nano-liquid chromatography-tandem mass spectrometry (a
               technique enabling the detection of extremely low concentrations of lyso-Gb3, with greater sensitivity than
               conventional techniques), in patients with variants of unknown significance (p.R112H and p.M296I),
               demonstrated that lyso-Gb3 was lower than in classical and late-onset phenotypes FD patients having other
               variants, but higher than in those with functional variants (p.E66Q) and healthy subjects [1,57] .

               The performance of urinary lyso-Gb3 as a diagnostic tool seems similar to that of plasma lyso-Gb3, with
               only a minority of patients excreting undetectable amounts and with patients presenting missense
               mutations or mutations associated with late-onset phenotypes having significantly lower excretion of lyso-
               Gb3 [33,47] . Thus, lyso-Gb3 seems to be a promising diagnostic biomarker, with added value for diagnosis in
               specific situations, but evaluation of pathogenicity of mutations based solely on this parameter should be
               cautious .
                      [1]

               Role in clinical monitoring
               Various correlations have been found between plasma lyso-Gb3 and clinical manifestations. However, as
               stated previously, given the large differences in plasma lyso-Gb3 levels between male and female genders or
               classical and late-onset phenotypes, a sub-analysis by these subgroups is paramount in order to avoid the
               confounding factor of disease severity (higher in males and classical phenotype) and to understand the true
               clinical correlations and prognostic value of plasma lyso-Gb3 in single patients, for whom the gender and
               phenotype are already known; thus, in a study with analysis by these sub-subgroups, only significant clinical
               correlations were found between plasma lyso-Gb3 in classical males and indexed LV mass, as well as
               between plasma lyso-Gb3 in classical females and total MSSI [Table 2] .
                                                                          [46]
   56   57   58   59   60   61   62   63   64   65   66